A5038238143- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Esophageal Cancer Research and Treatment
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Fibroblast Growth Factor Research
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Colorectal Cancer Surgical Treatments
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Biosimilars and Bioanalytical Methods
- Economic and Financial Impacts of Cancer
- Phagocytosis and Immune Regulation
- COVID-19 Clinical Research Studies
- Palliative Care and End-of-Life Issues
The University of Kansas Cancer Center
2016-2025
University of Kansas Medical Center
2020-2024
University Medical Center
2020-2023
University Hospital and Clinics
2023
The University of Texas Health Science Center at San Antonio
2010-2022
The University of Texas Health Science Center at Houston
2019-2022
University of Kansas
2019-2022
Shawnee Mission Medical Center
2021
Thomas Jefferson University Hospital
2020
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients advanced/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, that progressed one prior therapy, to pembrolizumab 200 mg every 3 weeks for up 2 years chemotherapy (investigator’s choice paclitaxel, docetaxel, irinotecan). Primary end points were...
This is the phase Ib part of I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). Thirty-five patients are enrolled. There no observed dose-limiting toxicities during dose escalation. The overall grade 3/4 treatment-related...
Abstract CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS tumors. Primary endpoint was met with ORR of 27.6% (95% CI 12.7-47.2%). Secondary endpoints 4-month PFS rate 44.83% 26.5-64.3%); and median OS 9.1 months 5.8-20.2). Grade≥3 TRAE occurred 39%. In post-hoc analysis RAS wild type tumors, 50% 6.3 21.5...
Objectives: To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas (HAPa); IND# 12311] immunotherapy combined with standard care (SOC) chemotherapy chemoradiation to SOC therapy alone in patients borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). Summary Background Data: date, has not been shown benefit unresectable PDAC. HAPa is a cancer vaccine consisting allogeneic cells engineered express murine α(1,3)GT gene. Methods: A multicenter,...
In the phase III KEYNOTE-181 study (NCT02564263) of patients with advanced esophageal cancer (EC), pembrolizumab monotherapy prolonged overall survival versus chemotherapy as second-line therapy in programmed death ligand 1 combined positive score (CPS) ≥ 10. We present results prespecified health-related quality-of-life (HRQoL) analyses squamous cell carcinoma (SCC), CPS 10, and 10 SCC populations.HRQoL was measured using European Organisation for Research Treatment Cancer (EORTC) Quality...
135 Background: Cabo is an anti-VEGFR2/MET/AXL drug with broad multi-kinase inhibitory spectrum. Preclinical and clinical studies in various solid tumors demonstrated favorable immune modulatory activity of synergy seen when combined PD-1/ PD-L1 inhibitors like Durva. Upon completion phase Ib gastrointestinal (GI) basket CAMILLA trial evaluating + Durva 30 patients (pts) demonstrating safety & efficacy, the was expanded to 2 multi-cohort, multi-center 117 pts. Herein, we report results...
The durability of the antibody response to COVID-19 vaccines in patients with cancer undergoing treatment or who received a stem cell transplant is unknown and may be associated infection outcomes.To evaluate anti-SARS-CoV-2 spike protein receptor binding domain (anti-RBD) neutralizing (nAb) responses longitudinally over 6 months (SCT).In this prospective, observational, longitudinal cross-sectional study 453 an SCT at University Kansas Cancer Center City, blood samples were obtained before...
Abstract Background Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect setting of metastatic and postoperatively. This study to assess ICI + chemotherapy perioperatively. Methods Patients with locally advanced (T1N1‐3M0 or T2‐3NanyM0) potentially resectable esophageal/gastric/GEJ adenocarcinoma by PET/EUS/CT staging‐laparoscopy, were treated preoperative 4 cycles mFOLFOX6...
4086 Background: Pemigatinib (PEMI), a potent, selective, oral FGFR1-3 inhibitor, has shown efficacy and safety in patients (pts) with CCA FGFR2 rearrangements/fusions FIGHT-202 (NCT02924376; objective response rate [ORR], 35.5%; duration of [DOR], 7.2 months [mo]). Overall survival (OS: 21.1 mo) was not mature the primary report (Abou-Alfa. Lancet Oncol 2020; cutoff: Mar 22, 2019); herein we matured data from (cutoff: Apr 7, 2020). Methods: Pts (≥18 y) known FGF/FGFR alterations progression...
TPS651 Background: Cholangiocarcinoma (CCA) is a highly aggressive cancer with limited treatment options. Trop-2, transmembrane calcium signal transducer, plays key role in cellular self-renewal, proliferation, and transformation, thereby promoting tumorigenesis. Its overexpression has been associated disease progression shorter survival several epithelial tumors, including CCA. Sacituzumab govitecan (SG) an antibody-drug conjugate composed of humanized anti-trophoblast cell-surface antigen...
108 Background: Genomic testing plays a pivotal role in personalizing treatment for CRC patients. Despite recommendations from NCCN, adoption remains uneven. Research indicates that only 64.7% of patients with metastatic (mCRC) underwent molecular nationwide. TEAMSPORT seeks to address this gap by evaluating the feasibility reflex and examining how pathology oncology teams integrate genomic into routine practice. Methods: This quasi-experimental study tracks over time. Eligible were 18 years...
PURPOSE In metastatic breast cancer (MBC), oral capecitabine prescribed at the US Food and Drug Administration (FDA)–approved dose of 1,250 mg/m 2 twice daily, 14 days on, 7 off, is associated with poor tolerance. Mathematical models suggest that a fixed-dose (FD), dose-dense schedule may optimize efficacy. We conducted randomized, open-label trial to compare efficacy tolerability FD capecitabine, 1,500 mg off (FD-7/7), FDA-approved (standard-dose [SD]-14/7). METHODS Females MBC any previous...
Ampullary cancers represent a subset of periampullary cancers, comprising only 0.2% all gastrointestinal cancers. Localized disease is primarily managed by surgical intervention, called pancreaticoduodenectomy (PD), followed in many cases the administration adjuvant chemotherapy (CT) or chemoradiation therapy (CRT). However, there are no clear evidence-based guidelines to aid selecting both modality and regimen for resected carcinoma. We retrospectively analyzed 54 patients at KU Cancer...
1007 Background: In metastatic breast cancer (MBC), oral capecitabine prescribed at the FDA approved dose of 1250 mg/m 2 twice daily, 14 days on followed by 7 off, is associated with poor tolerance and high discontinuation rates. Mathematical models suggest a fixed dose, dense (7 on, off) schedule may be optimal for efficacy. We conducted randomized trial to compare efficacy tolerability fixed-dose capecitabine, 1500 mg off (FD) (SD). Methods: Females MBC any prior lines endocrine therapy or...
Sorafenib is the only FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often required, although there limited efficacy data related to modifications. Given prevalence of HCC in South Texas, we assessed and safety sorafenib relation Child Pugh (CP) score.A retrospective analysis was done patients, starting at 400 mg twice daily, or physician discretion with goal titrating daily. Overall survival (OS) progression-free (PFS)...
There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response treatment more efficiently than imaging. We report an innovative approach will generate renewed interest in using circulating tumor cells (CTCs) monitor efficacy, which, this case, used PDAC patients receiving exploratory therapy, poly ADP-ribose polymerase inhibitor (PARPi)—niraparib—as case study. CTCs...
4563 Background: Cabo targets multiple tyrosine kinases, including VEGFR, MET, and AXL, has been reported to show immunomodulatory properties that may counteract tumor-induced immunosuppression, providing a rationale for combining it with PD-L1 inhibitors like durva. We conducted phase Ib GI basket trial evaluate the safety & efficacy of this regimen in advanced GE adenocarcinoma (GEA), colorectal cancer (CRC), hepatocellular carcinoma (HCC). Methods: Patients received cabo durva 3+3...